Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526926 · ClinicalTrials.gov registry record
A Post-Marketing Observational Study of VYXEOS™
A clinical trial, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- 52
- Enrollment target
NCT03526926 is a clinical trial that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 52 participants.
The verdict
NCT03526926 has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- 52 participants
- Enrollment target
Study Summary
The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.
Interventions
- DRUG CPX-351
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2020-06-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03526926
The ClinicalTrials.gov registry entry for NCT03526926 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CPX-351 is the first listed.
NCT03526926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03526926 about?
NCT03526926 is a clinical study titled "A Post-Marketing Observational Study of VYXEOS™". The purpose of this observational study is to provide data on the incidence and severity of infusion-related reactions during and immediately following each infusion of VYXEOS during the first induction.
What is the current status of trial NCT03526926?
This trial is currently completed. The enrollment target is 52 participants. The study started on 2018-10-23. Estimated completion is 2020-06-12.
What interventions are being tested in trial NCT03526926?
The interventions under investigation include: CPX-351 (DRUG).
Who is sponsoring clinical trial NCT03526926?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.